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Abstract
Background: Metastases to the pancreas are rare, and usually mistaken for primary pancreatic cancers. This study
aimed to describe the histology results of solid pancreatic tumours obtained by endoscopic ultrasound-guided fine-
needle aspiration (EUS-FNA) for diagnosis of metastases to the pancreas.
Methods: In a retrospective review, patients with pancreatic solid tumours and history of previous extrapancreatic
cancer underwent EUS-FNA from January/1997 to December/2010. Most patients were followed-up until death and
some of them were still alive at the end of the study. The performance of EUS-FNA for diagnosis of pancreatic
metastases was analyzed. Symptoms, time frame between primary tumour diagnosis and the finding of metastases,
and survival after diagnosis were also analyzed.
Results: 37 patients underwent EUS-FNA for probable pancreas metastases. Most cases (65%) presented with
symptoms, especially upper abdominal pain (46%). Median time between detection of the first tumour and the
finding of pancreatic metastases was 36 months. Metastases were confirmed in 32 (1.6%) cases, 30 of them by EUS-
FNA, and 2 by surgery. Other 5 cases were non-metastatic. Most metastases were from lymphoma, colon, lung, and
kidney. Twelve (32%) patients were submitted to surgery. Median survival after diagnosis of pancreatic metastases
was 9 months, with no difference of survival between surgical and non-surgical cases. Sensitivity, specificity, positive
and negative predictive values, and accuracy of EUS-FNA with histology analysis of the specimens for diagnosis of
pancreatic metastases were, respectively, 93.8%, 60%, 93.8%, 60% and 89%.
Conclusion: EUS-FNA with histology of the specimens is a sensitive and accurate method for definitive diagnosis of
metastatic disease in patients with a previous history of extrapancreatic malignancies.
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Background
Pancreatic metastases (PM) are rare [1], accounting for
3% of pancreatic solid tumours submitted to surgical
resection [2]. PM can be identified during staging of a
disseminated cancer or during periodic control of a pri-
mary cancer treated several months or years before [3,4].
More rarely, PM can be found even before the detection
of the primary tumour, a situation in which the poor
prognosis and low rate of resectability are well known
[5-7]. The misdiagnosis of a primary pancreatic cancer
can be avoided by performing a preoperative biopsy, ei-
ther through a percutaneous radiologic method (US or
CT) or by endoscopic ultrasound-guided fine-needle as-
piration (EUS-FNA) [8].
EUS-FNA is the least invasive and most effective
method for diagnosis of pancreatic tumours [8,9]. How-
ever, its importance for diagnosis of PM has been
reported only by description of isolated cases [6,7,10-20]
or small case series [3,4,21-23] describing and compar-
ing PM endosonographic imaging and cytological find-
ings with primary pancreatic cancer [3]. There is no
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large case series with history of previous extra-pancreatic
malignancy followed-up until death in which the diagnosis
of PM has been made through the histology obtained by
EUS-FNA.
The aim of this study was to determine the incidence,
clinical characteristics, endosonographic patterns, sur-
vival, and performance of the EUS-FNA in a large case
series suspicious for PM.
Methods
Patients
Between January 1997 and December 2010, 1986 pa-
tients with radiological evidence for a solid pancreatic
tumour or enlargement of the pancreatic head under-
went EUS-FNA at Endoscopic Ultrasound Units from
Hospital 9 de Julho and Hospital das Clínicas / Ribeirão
Preto Medical School. This retrospective study was based
on the microhistologic analysis of pancreatic metastases
obtained by EUS-FNA from patients with or without a
previous history of extrapancreatic cancer. Those whose
pathology examination obtained at the time of surgery or
EUS-FNA had no definitive diagnosis of a pancreatic neo-
plasia (atypia, suspicion of malignancy, and insufficient
material for immunohistochemistry), patients with a pan-
creatic mass, history of previous extrapancreatic cancer
and FNA confirming a primary pancreatic cancer, as well
as those with a primary pancreatic lymphoma were ex-
cluded. Ethical approval for this retrospective study was
obtained from both institutional review boards.
Demographics, clinical features and endosonographic
findings were recorded. The information about every
case was obtained through e-mail and/or phone call to
the referring physicians and family members, and by re-
view of the medical charts. Only the radiologist and
pathologist were blinded to the history of previous can-
cer for all the patients in this study.
EUS-FNA
Once informed consent was obtained for the procedure,
patients were sedated with propofol associated with
midazolam and fentanyl under cardiorespiratory moni-
toring. All procedures were performed by the same
echoendoscopist with a large experience in diagnostic
and therapeutic echoendoscopy (JCA). The sectorial
echoendoscopes used were: Pentax FG 38-UX (Pentax
Precision Instruments Corp., Orangeburg, New York)
coupled to an ultrasound unit EUB 515 (Mitsubishi,
Conshockon, Philadelphia), Olympus UCT-160 OL5
(Olympus Optical Corp., Ltd., Tokyo, Japan) coupled to
an ultrasound unit UC-60 (Suzy-Olympus Optical Corp.
Ltd., Tokyo, Japan), and Fujinon EG-530UT (Fujifilm
Optics Corp. Ltd., Sano, Japan) coupled to an ultra-
sound unit SU7000 (Kodai Hi Tec Corp. Ltd., Saitama,
Japan). Only needles of 22 gauge and length of 145 cm
(Medi Globe, Medizintechnik GMBH, Grassau/Germany)
were used for all the punctures. The endosonographic fea-
tures taken into account were: location, size, echotexture,
homogeneity, borders and proximity to blood vessels.
After puncturing the tumour, core specimens were
obtained by flushing the needle with 2 ml of saline and
then by reintroduction of the stylet inside the needle. All
material was placed in 10% buffered neutral formalin solu-
tion. As an on-site cytopathologist was not available in
our routine, the specimens were considered satisfactory in
the presence of non-hemorrhagic small tissue filaments or
tissue core samples. The specimens were sent to a path-
ologist (FV), and prepared according to a previously de-
scribed cell block technique [24].
Statistical analysis
Statistical analysis of continuous variables was described
as mean and standard deviation, and dichotomous vari-
ables were expressed as simple ratios. The sensitivity,
specificity, positive and negative predictive values, and
accuracy of the histology findings obtained by EUS-FNA
for the diagnosis of PM were calculated, as well as their
95% confidence intervals. Sensitivity was used to evalu-
ate the capacity of the EUS-FNA to detect the patients
that were known to have pancreatic metastases. Specifi-
city was used to evaluate the capacity of the EUS-FNA
to confirm the cases that were known not to have pan-
creatic metastases. The positive predictive value analysed
how likely patients with pancreatic metastases detected
by EUS-FNA actually did have the finding, and the nega-
tive predictive value analysed how likely patients without
detection of pancreatic metastases by EUS-FNA actually
did not have the finding.
Results
Patients
Fifty-two patients (2.6%) were identified. After applying
exclusion criteria for suspicious lesions for PM, 37 pa-
tients were selected. Their demographics are presented
in the Table 1. All patients were evaluated by computed
tomography before the EUS-FNA, which detected a pan-
creatic mass in 32 (85%) cases, an increase in size of the
pancreatic head with jaundice but no focal mass in 2
(6%) cases, a normal pancreas in another two (6%) cases
(one of them with jaundice), and a segmental dilation of
the main pancreatic duct in 1 (3%) patient. One case mis-
taken by CT as a gastric subepithelial tumour with normal
pancreas was revealed by EUS as a pancreatic mass.
EUS evaluation
The average size of the lesions was 42 ± 11 mm
(range:12–127 mm). Lesions were located preferably in
the head of the pancreas (21), but also in the body (9),
tail (4), neck (1), body/tail (1) and head/body/tail (1).
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Most of the lesions were solid [32 (86%)], 4 were solid-
cystic (esophageal cancer, renal cancer, mesothelioma,
and tuberculosis) and one cystic (IPMN). In most cases
lesions were solitary (34), hypoechoic (34), with well-
defined borders (23) and heterogeneous (22) (Figure 1).
Only 2 (5.4%) of them were hyperechoic (esophageal
cancer and plasmocytoma) and another one was an-
echoic (IPMN). PM were hypervascular in 3 cases where
Doppler signal was positive [renal (2) and hepatocellular
carcinoma (1)].
EUS-FNA was successfully performed in all 37 pa-
tients after an average of 2.4 needle passes (range: 2–4).
The final diagnosis was obtained in 35 (94%) cases: 30/
35 confirmed the clinical suspicion for PM [lymphoma
(6), colon (4), renal clear cell (4), lung (3), breast (2),
leiomyosarcoma (2), stomach (1), esophageal (1), gallblad-
der (1), hepatocellular carcinoma (1), mesothelioma (1),
myeloma (1), ovarian (1), rhabdomyosarcoma (1), and
melanoma (1)]. A primary pancreatic neoplasm was con-
firmed in 3 cases [IPMN (1), NET (1) and adenocarcin-
oma (1)], and in 2 cases a pancreatic pseudotumour was
found (pancreatic blastomycosis and tuberculosis). In the
remaining 2 cases, the diagnosis obtained by EUS-FNA
was chronic pancreatitis, but surgical resection confirmed
a PM (gastric and lung cancer) (Additional file 1).
Twelve patients with pancreatic tumours were submit-
ted to surgery. Four patients underwent exploratory
laparotomy [colon cancer (2), gastric cancer (1) and NET
(1)], 5 were submitted to gastroduodeno-pancreatectomy
(colon, gastric, lung, renal clear cell and ductal adenocar-
cinoma) and 3 underwent subtotal pancreatectomy (renal
clear cell (2), and lung cancer). The final diagnosis was
colon cancer (3), renal clear cell (3), gastric cancer (2),
lung cancer (2), ductal adenocarcinoma (1) and NET (1).
Surgical diagnosis of PM was confirmed by histology
obtained by EUS-FNA in 10 of 12 cases.
Clinical impact of EUS-FNA
Metastases were confirmed in 32 cases. The incidence in
this series was 1.6%. EUS-FNA confirmed the diagnosis
of PM in 30/32 (94%) cases. For 29 cases with diagnosis
of PM during cancer control, the mean and median time
between diagnosis of the primary tumour and the PM
were, respectively, 50.2 (2–360 m) and 36 months. For
two patients in whom CT revealed nonspecific increase
in the size of the pancreatic head, EUS-FNA made the
diagnosis of lymphoma and PM from breast cancer. The
first patient had been treated for non-Hodgkin's lymph-
oma for 6 months, and the other patient underwent sur-
gery for breast cancer 5 years previously. The case in
which CT showed only dilation of the main pancreatic
duct, the patient had undergone surgery for a breast
cancer 5 years earlier. Endosonographic features were
suspicious for PM, but histology revealed a primary pan-
creatic adenocarcinoma, which was confirmed after
surgical resection. In the patient presenting with jaun-
dice and a normal CT, who had been treated for a non-
Hodgkin's lymphoma for 6 months, EUS-FNA confirmed
the diagnosis of PM from lymphoma. In the patient whose
CT revealed a normal pancreas and showed a subepithelial
gastric tumour, EUS-FNA detected a PM for ovarian can-
cer. In 3 patients in which EUS imaging was suspicious for
Table 1 Demographic findings of the patients
Characteristics n (%)
Age (average) 60.3y (26–84 y)
Gender (male/female) 26 (70) / 11 (30)
Symptoms 24 (65)
Abdominal pain 11
Abdominal pain + weight loss 6
Jaundice 5
Acute pancreatitis 2
Asymptomatic 13 (35)
Diagnosis of metastases
Control of disease 29 (78)
Non-Hodgkin lymphoma 6
Colon cancer (adenocarcinoma) 4
Renal cancer (clear renal cell cancer) 4
Breast cancer 3
Sarcoma [Leyomiossarcome (1),
Rhabdomiossarcome (1) and sarcoma (1)]
3
Gastric cancer (adenocarcinoma) 2
Skin cancer (melanoma) 2
Bladder cancer 1
Esophageal cancer (squamous cell carcinoma) 1
Gallbladder cancer 1
Lung cancer (NSCLG) 1
Mieloma Multiplus (Plasmocytoma) 1
Before identification of the primary cancer 6 (15)
Renal cancer (clear renal cell cancer) 1
Lung [SCLC(1) and squamous cell carcinoma (2)] 3
Ovarian cancer 1
Mesothelyoma 1
Initial Staging 2 (6)
Gastric cancer (signet ring cells adenocarcinoma) 1
Liver (hepatocellular carcinoma) 1
NSCLC: non-small cell lung cancer; SCLG: small cell lung cancer.
Control of disease: periodical control of a previously identified
extrapancreatic tumour.
Before identification of the primary cancer: Imaging methods revealed a
pancreatic mass, and EUS-FNA confirmed it as a metastatic tumour, without
detection of the primary cancer.
Initial staging: an extrapancreatic tumour and a pancreatic mass or
enlargement were detected at the same time.
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a NET, EUS-FNA detected metastases [clear cell cancer (2)
and hepatocellular carcinoma]. One patient with a pancre-
atic mass had had a nephrectomy for a renal cell tumour
30 years earlier and had a well-defined pancreatic nodule,
which was resected. EUS-FNA made the diagnosis of
PM prior to identification of the primary tumour in 6
(16%) patients [lung (3), kidney (1), mesothelioma (1)
and ovarian cancer (1)]. Clinical features, treatment and
follow-up of the remaining patients with clinical history
of extrapancreatic cancer submitted to EUS-FNA are
presented in the Additional file 1.
For calculations of sensitivity, specificity, positive and
negative predictive values, and accuracy of EUS-FNA for
diagnosis of PM, the patients with infectious pancreatic
involvement mimicking a pancreatic mass, and the pa-
tient with IPMN were considered as true negatives;
those in which EUS-FNA revealed chronic pancreatitis
were considered as false negatives, and cases of NET and
pancreatic adenocarcinoma, as false positives. The per-
formance of EUS-FNA for diagnosis of PM are presented
in the Table 2.
Long-term follow-up after EUS-FNA
Most patients were followed-up until death. At the end
of the study, only three of the patients with PM, 2 of
them from renal clear cell cancer, and another one from
breast cancer, were still alive, 6, 12 and 22 months, re-
spectively, after EUS-FNA. The remaining 29 patients
died, and the mean and median survival after diagnosis
of PM were, respectively, 15.1 (range: 4–89 months) and
9 months. There was no significant difference in the me-
dian survival between patients who received surgery and
those who did not (9 vs. 8.5 months).
Discussion
Isolated pancreatic masses are usually primary pancreatic
tumours, either ductal adenocarcinoma or neuroendo-
crine neoplasia, or represent focal chronic pancreatitis [3].
Secondary involvement of the pancreas by extrapancreatic
cancer is rare and constitutes less than 3% of all pancreatic
resections [2,4,25-27], though the rate varies between 3%
and 12% of all pancreatic malignancies in autopsy studies
[28]. Even though rare, the literature demonstrates the
pancreas as a site for metastases from some cancers,
especially renal, ovarian, breast, lung, brain and colon
[2,4,6,7,23]. This data was corroborated by the findings of
Figure 1 Asymptomatic patient (n° 37) submitted to surgery due to clear renal cell cancer 30 years ago. (a) EUS revealed a hypoechoic,
homogeneous, with well-defined borders lesion in the pancreatic body. (b) Histology obtained by EUS-FNA of the lesion was suggestive of a
renall cancer. (c) Imunohistochemistry with positive reaction for acidic cytokeratins (AE1) and (d) CD10 confirmed a metastasis from clear renal
cell cancer.
Table 2 Performance of EUS-FNA for diagnosis of
pancreatic metastases
95% CI
Sensitivity 93.8% 85% -100%
Specificity 60% 17% -100%
Positive predictive value 93.8% 85% -100%
Negative predictive value 60% 17% -100%
Accuracy 89% 79% - 99%
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our series as well, with higher prevalence of non-Hodgkin's
lymphoma, lung, renal, colon and breast cancer.
Patients presenting with pancreatic metastases often
have non-specific symptoms. Patients can present with
abdominal pain, weight loss, nausea, melaena, jaundice,
and gastric outlet obstruction. Abdominal pain was the
most frequent symptom in our patients, which was
present in 46% of the patients. However, patients with
pancreatic metastases can be asymptomatic in up to 35%
of these cases [29]. This way, the symptomatology al-
most nothing contributes for diagnosis of a pancreatic
metastases.
Some cases are encapsulated and hypervascular and
may be similar to lymph nodes or pancreatic NETs
[30,31], fact which occurred in 5 of our patients. Never-
theless, there is no pathognomonic imaging feature to
make it possible to distinguish a PM from a primary
pancreatic cancer [32-35]. This also occurred in our
study, where CT did not suspect for a PM in any case.
In our series, endosonographic characteristics of PM
were similar to those found in primary pancreatic cancer
in up to 50% of these cases, and small lesions tended to
have well-defined borders, highly suggestive for pancre-
atic neuroendocrine tumours [3,4,21,22]. In the experi-
ence by DeWitt et al. [3], 46% of PM had well-defined
borders when compared to 4% of primary pancreatic tu-
mours (p<0.0001). Bechade et al. [36] demonstrated
well-defined borders in 10/11 patients with PM from
renal cancer.
As it is not possible to identify a typical endosonographic
image for a PM, it seems reasonable to assume that the
identification by EUS of a heterogeneous pancreatic mass
with well-defined borders in a patient with a previous
history of malignancy should firstly raise the suspicion
for a PM, and EUS-FNA should be used to confirm the
diagnosis. At this moment, we need to highlight the im-
portance of the histopathologic diagnosis of the solid
pancreatic lesions, which can avoid unnecessary surgery
for non-neoplastic tumours, such as lymphoma, myco-
ses and tuberculosis, which were detected in almost
22% of our cases, all of them confirmed by EUS-FNA.
Conversely, surgical resection can be indicated and offer
a good survival for PM in selected patients, especially
for renal tumours [27,37], which could be observed in 2
out of 4 patients with clear renal cell cancer submitted
to surgery in our study, both of them still alive after 6
and 12 months. The use of histology was effective and
made the correct diagnosis of PM in 94% of the cases in
our experience.
Due to the absence of studies evaluating the histology
of PM obtained by EUS-FNA, the authors believe this
study has a considerable value. We found that EUS-FNA
had a major clinical impact in 86% of patients with PM.
It detected PM in patients whose CT only identified a
pancreatic mass and labeled it as cancer, without raising
the possibility of a PM. In addition, EUS-FNA detected
the presence of PM prior to the identification of the new
primary tumour in 6 (18%) cases, 5 of them confirmed
by EUS after identification of a mass on CT, and another
one in which CT demonstrated a subepithelial gastric
tumour.
Unlike other studies which included patients only after
a positive diagnosis of PM, we selected only cases with a
previous treatment for an extrapancreatic cancer which,
during their clinical follow-up, presented a pancreatic
mass on CT, and were afterwards submitted to EUS-FNA
[3,22]. Therefore, performance of histology obtained by
EUS-FNA for diagnosis of PM could be assessed. Sensitiv-
ity, specificity, positive and negative predictive values, and
accuracy of EUS-FNA with histology analysis of the speci-
mens for diagnosis of PM were, respectively, 93.8%, 60%,
93.8%, 60% and 89%. Despite a good accuracy, we must
point out that historical inaccuracies and biases are un-
avoidable in a retrospective database analysis, and the fig-
ures drawn from it must be taken cautiously. Two of our
patients were found to have PM from previously unknown
primary cancers. Besides, it is still possible that other pa-
tients with an unknown primary cancer may have under-
gone EUS-FNA for a pancreatic mass and may have a
non-diagnostic histology sample. These patients would
not be included and therefore will not appear as false
negative cases. This raises the question about whether all
PM has been included in the study, and could explain the
low specificity and negative predictive values of the study.
As we know so far, there is no study evaluating the
performance of the histology obtained by EUS-FNA for
the diagnosis of PM. Fritscher-Ravens et al. [21] evalu-
ated the role of the cytopathology for the diagnosis of
PM in specimens obtained by EUS-FNA in a study with
a small number of PM. Sensitivity, specificity, positive
and negative predictive values, and accuracy were, re-
spectively, 88%, 100%, 100%, 80%, and 92%. These re-
sults were somewhat better when compared with our
figures. However, the endosonographer performing the
procedure was trained for cytopathologic evaluation of
the specimens. This way, despite the absence of an on-
site cythopathologist, a better managing of the speci-
mens could be offered in the moment of the exam. Be-
sides, we need to remember that there was a very small
number of patients, which is very important, because a
larger number of cases with cytopathology revealing
adenocarcinoma might constitute an important drawback
for the differential diagnosis between a primary pancreatic
malignancy and a PM, demanding more laborous tech-
niques, such as imunocytochemistry and detection of spe-
cific tumoral markers. Moreover, the authors did not
comment on the time required for each endoscopic pro-
cedure with cytophathologic evaluation. On the other
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hand, EUS-FNA with sampling for histology analysis with-
out on-site cytopathologist neither required additional
time for the endoscopic procedure, nor additional training
for the endosonographer in regard to the management of
the specimens. So, this approach with a very good sensitiv-
ity and accuracy for PM, could be more convenient and
practical for the majority of the endosonographers work-
ing without on-site cytopathologists and expertise for the
handling and evaluation of the aspirated material.
Conclusions
This study demonstrates that PM should be considered
in the presence of a solid pancreatic lesion in patients
with a history of a previous extrapancreatic cancer, re-
gardless of the time elapsed from the occurrence of the
primary cancer. EUS-FNA with histology of the speci-
mens is the best method for definitive diagnosis of pan-
creatic disease in this group of patients
Additional file 1
Additional file 1: Clinical features, treatment and follow-up of
patients with clinical history of extrapancreatic cancer submitted to
EUS-FNA. Symptoms - AP: abdominal pain; J: jaundice; WL: weight loss;
AcP: acute pancreatitis. Treatment – CT: chemotherapy; RT: radiotherapy.
Surgery - W: Whipple procedure; EL: exploratory laparotomy; SP: subtotal
pancreatectomy. n/a: not applicable.
Abbreviations
EUS-FNA: Endoscopic ultrasound-guided fine-needle aspiration;
PM: Pancreatic metastases; US: Ultrasound; CT: Computed tomography;
IPMN: Intraductal papillary mucinous neoplasia; NET: Neuroendocrine
tumour.
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